WNT1 and osteoporosis: In conclusion, our study demonstrates that the circulating levels of lipocalin-2 are not altered in WNT1 and PLS3 osteoporosis, and therefore cannot be used as a metabolic biomarker in the diagnosis or for monitoring these two monogenic conditions.